Register Login

MAZE THERAPEUTICS, INC. (MAZE)

SymbolMAZE
NameMAZE THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address171 OYSTER POINT BOULEVARD,SUITE 300, SAN FRANCISCO, California, 94080, United States
Telephone6508505070
Fax—
Email—
Websitehttps://www.mazetx.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001842295
Description

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. We initiated a Phase 2 trial of our lead drug candidate, MZE829, in November 2024.

Additional info from NASDAQ:
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. We initiated a Phase 2 trial of our lead drug candidate, MZE829, in November 2024.

2026-08-17 20:52

Kornowski Sophie 🟢 acquired 36.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $27.66 Transaction Date: Aug 13, 2026 | Filing ID: 000006

Read more
2026-08-17 20:51

Johnson Paula A 🟢 acquired 36.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $27.66 Transaction Date: Aug 13, 2026 | Filing ID: 000005

Read more
2026-08-17 20:16

(75% Positive) MAZE THERAPEUTICS, INC. (MAZE) Provides Update on initiations for both molecules next year

Read more
2026-08-17 17:49

New Form 3 - Maze Therapeutics, Inc. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001894117-26-000005 <b>Size:</b> 10 KB

Read more
2026-08-17 17:46

New Form 3 - Maze Therapeutics, Inc. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001341161-26-000003 <b>Size:</b> 10 KB

Read more
2026-08-14 20:54

Bernstein Harold 🟡 adjusted position in 16.1K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $27.61 Transaction Date: Aug 13, 2026 | Filing ID: 000028

Read more
2026-08-14 17:28

New Form SCHEDULE 13G/A - Maze Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097205 <b>Size:</b> 12 KB

Read more
2026-08-13 20:42

Maze Therapeutics Announces Appointments to Its Board of Directors

Read more
2026-08-11 20:45

(30% Negative) MAZE THERAPEUTICS, INC. (MAZE) Reports Q3 2026 Financial Results

Read more
2026-08-11 20:01

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Read more